Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Pressure pain threshold in the craniocervical muscles of women with episodic and chronic migraine A controlled study

Full text
Author(s):
Grossi, Debora Bevilaqua [1] ; Chaves, Thais Cristina [1] ; Goncalves, Maria Claudia [1] ; Moreira, Viviane Coimbra [1] ; Canonica, Alexandra Carolina [1] ; Florencio, Lidiane Lima [1] ; Bordini, Carlos Alberto [1] ; Speciali, Jose Geraldo [1] ; Bigal, Marcelo Eduardo [1]
Total Authors: 9
Affiliation:
[1] Univ Sao Paulo, Sch Med Ribeirao Preto FMRP, Ribeirao Preto, SP - Brazil
Total Affiliations: 1
Document type: Journal article
Source: Arquivos de Neuro-Psiquiatria; v. 69, n. 4, p. 607-612, AUG 2011.
Web of Science Citations: 32
Abstract

Objective: To estimate the pressure pain threshold (PPT) of the craniocervical muscles in women with episodic migraine (EM) n=15 and chronic migraine (CM) n=14, and in healthy volunteers (C) n=15. Method: A blinded examiner obtained the PPT bilaterally, by pressure algometry, for the following muscles: frontalis, temporalis, masseter, trapezius and sternocleidomastoid. ANOVA (p<0.05) was used for statistical purposes. Results: Contrasted to controls, individuals with EM had significantly decreased PPT values for frontal muscle (EM: 2.01 +/- 0.67 vs. C: 2.85 +/- 0.71), posterior temporalis bilaterally (right and left, respectively) (EM: 2.72 +/- 0.89 vs. C: 3.36 +/- 0.72 and EM: 2.60 +/- 1.00 vs. C: 3.35 +/- 0.85), upper trapezius bilaterally (EM: 2.69 +/- 1.00 vs. C: 3.49 +/- 0.83 and EM: 2.54 +/- 0.93 vs. C: 3.32 +/- 0.97) and women with CM: on frontal muscle bilaterally (CM: 2.16 +/- 0.52 vs. C: 2.79 +/- 0.71 and CM: 2.01 +/- 0.67 vs. C: 2.85 +/- 0.71) and upper trapezius (CM: 2.66 +/- 0.84 vs. C: 3.32 +/- 0.97), however, it was not verified differences between PPT values between EM and CM groups. Conclusion: PPT is decreased in women with migraine relative to controls. Future studies should explore this parameter as a biological marker of the disease and a predictor of treatment. (AU)